Nanotechnology as a tool to overcome macromolecules delivery issues

Tundisi, Louise Lacalendola; Ataide, Janaína Artem; Costa, Juliana Souza Ribeiro; Coêlho, Diego F.; Liszbinski, Raquel Bester; Lopes, André Moreni; Jesus, Marcelo Bispo de; Jozala, Ângela Faustino; Ehrhardt, Carsten; Mazzola, Priscila Gava

doi:10.1016/j.colsurfb.2022.113043

Cited by 24 publications

(13 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another way to enhance treatment options of various diseases is the use of nanostructures as drug delivery systems. Nanocarriers can improve drugs’ bioavailability, solubility, and permeability, increase drugs’ half-lives in the organism, and decrease the toxicity, as well as promote targeted or controlled release [ 18 , 19 , 20 ]. Even though different studies have already suggested the use of nanotechnology-based co-delivery systems, there are still challenges to be addressed, including some that are well known for single-drug encapsulation, such as loading efficiency and nanoparticles’ properties [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

“…Nanocarriers can improve drugs’ bioavailability, solubility, and permeability, increase drugs’ half-lives in the organism, and decrease the toxicity, as well as promote targeted or controlled release [ 18 , 19 , 20 ]. Even though different studies have already suggested the use of nanotechnology-based co-delivery systems, there are still challenges to be addressed, including some that are well known for single-drug encapsulation, such as loading efficiency and nanoparticles’ properties [ 18 ]. Other challenges are related to encapsulating drugs with different physicochemical properties and solubility, and regulating sequential release [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Co-Encapsulation of Drugs for Topical Application—A Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

Achieving the best possible outcome for the therapy is the main goal of a medicine. Therefore, nanocarriers and co-delivery strategies were invented to meet this need, as they can benefit many diseases. This approach was applied specifically for cancer treatment, with some success. However, these strategies may benefit many other clinical issues. Skin is the largest and most exposed organ of the human body, with physiological and psychological properties. Due to its exposition and importance, it is not difficult to understand how many skin diseases may impact on patients’ lives, representing an important burden for society. Thus, this review aims to summarize the state of the art in research concerning nanocarriers and co-delivery strategies for topical agents’ applications targeting skin diseases. The challenge for the medicine of the future is to deliver the drug with spatial and temporal control. Therefore, the co-encapsulation of drugs and the appropriate form of administration for them are so important and remain as unmet needs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Co-Encapsulation of Drugs for Topical Application—A Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nanoparticles have emerged as a promising tool to overcome macromolecular drug-related problems, such as low permeability through biological membranes, short biological half-life, large size, high molecular weight, and structural instability [ 54 , 55 , 56 , 57 , 58 ]. Nanoparticles vary depending on their size, structure, function, and use.…”

Section: Biomedical Landscape Of Nanotechnologymentioning

confidence: 99%

Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment

Tariq

Qadeer²,

Anjum

et al. 2023

Biosensors

View full text Add to dashboard Cite

Thalassemia is a monogenic autosomal recessive disorder caused by mutations, which lead to abnormal or reduced production of hemoglobin. Ineffective erythropoiesis, hemolysis, hepcidin suppression, and iron overload are common manifestations that vary according to genotypes and dictate, which diagnosis and therapeutic modalities, including transfusion therapy, iron chelation therapy, HbF induction, gene therapy, and editing, are performed. These conventional therapeutic methods have proven to be effective, yet have several disadvantages, specifically iron toxicity, associated with them; therefore, there are demands for advanced therapeutic methods. Nanotechnology-based applications, such as the use of nanoparticles and nanomedicines for theragnostic purposes have emerged that are simple, convenient, and cost-effective methods. The therapeutic potential of various nanoparticles has been explored by developing artificial hemoglobin, nano-based iron chelating agents, and nanocarriers for globin gene editing by CRISPR/Cas9. Au, Ag, carbon, graphene, silicon, porous nanoparticles, dendrimers, hydrogels, quantum dots, etc., have been used in electrochemical biosensors development for diagnosis of thalassemia, quantification of hemoglobin in these patients, and analysis of conventional iron chelating agents. This review summarizes the potential of nanotechnology in the development of various theragnostic approaches to determine thalassemia-causing gene mutations using various nano-based biosensors along with the employment of efficacious nano-based therapeutic procedures, in contrast to conventional therapies.

show abstract

“…This leads to increased dosages, decreased patient compliance, and the need for alternative delivery routes [ 4 , 5 ]. Therefore, enhancing the solubility of poorly soluble drugs for oral administration represents a significant challenge [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability

Lee,

Yun

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Enzalutamide (ENZ), marketed under the brand name Xtandi® as a soft capsule, is an androgen receptor signaling inhibitor drug actively used in clinical settings for treating prostate cancer. However, ENZ’s low solubility and bioavailability significantly hinder the achievement of optimal therapeutic outcomes. In previous studies, a liquid self-nanoemulsifying drug delivery system (L-SNEDDS) containing ENZ was developed among various solubilization technologies. However, powder formulations that included colloidal silica rapidly formed crystal nuclei in aqueous solutions, leading to a significant decrease in dissolution. Consequently, this study evaluated the efficacy of adding a polymer as a recrystallization inhibitor to a solid SNEDDS (S-SNEDDS) to maintain the drug in a stable, amorphous state in aqueous environments. Polymers were selected based on solubility tests, and the S-SNEDDS formulation was successfully produced via spray drying. The optimized S-SNEDDS formulation demonstrated through X-ray diffraction and differential scanning calorimetry data that it significantly reduced drug crystallinity and enhanced its dissolution rate in simulated gastric and intestinal fluid conditions. In an in vivo study, the bioavailability of orally administered formulations was increased compared to the free drug. Our results highlight the effectiveness of solid-SNEDDS formulations in enhancing the bioavailability of ENZ and outline the potential translational directions for oral drug development.

show abstract

Nanotechnology as a tool to overcome macromolecules delivery issues

Cited by 24 publications

References 219 publications

Co-Encapsulation of Drugs for Topical Application—A Review

Co-Encapsulation of Drugs for Topical Application—A Review

Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment

The Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability

Contact Info

Product

Resources

About